Compare NIO & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NIO | CORT |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 9.7B |
| IPO Year | 2018 | 2001 |
| Metric | NIO | CORT |
|---|---|---|
| Price | $3.67 | $113.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 5 |
| Target Price | $6.73 | ★ $96.50 |
| AVG Volume (30 Days) | ★ 33.8M | 823.3K |
| Earning Date | 06-02-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.09 |
| Revenue | N/A | ★ $761,407,000.00 |
| Revenue This Year | $52.58 | $26.08 |
| Revenue Next Year | $18.91 | $26.98 |
| P/E Ratio | ★ N/A | $1,224.56 |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $3.55 | $28.66 |
| 52 Week High | $8.02 | $126.38 |
| Indicator | NIO | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 30.10 | 52.88 |
| Support Level | N/A | $108.25 |
| Resistance Level | $5.22 | $124.30 |
| Average True Range (ATR) | 0.11 | 5.29 |
| MACD | 0.00 | -0.76 |
| Stochastic Oscillator | 19.05 | 61.04 |
Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations, such as battery swapping and autonomous driving. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold around 326,000 EVs in 2025, accounting for about 2% of China's passenger new energy vehicle market.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.